Newsletters - Nov 2002

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

Sabinsa Corporation's R & D staff have developed and validated an HPLC assay procedure that has recently been approved by the United States Pharmacopeial Convention. As a courtesy, Sabinsa has sent this method to the leading analytical labs that service the dietary supplements industry. "It is part of our ongoing commitment to raise the consciousness and quality of dietary supplement ingredients. 

Sabinsa's Selenium SeLECT is currently the focus of a large-scale prostate cancer study funded through the National Institute of Health's (NIH) National Cancer Institute (NCI). It is the only selenium source being administered in the study. A second study recently was undertaken to evaluate selenomethionine's potential role in Alzheimer's patients.

The USP monograph for Selenomethionine is based on Sabinsa's Selenium SeLECT® brand L-(+)-Selenometahionine.

    HEADQUARTERS

  • Sabinsa Corporation
    20 Lake Drive
    East Windsor
    NJ 08520, USA

  • +1 732 777 1111
  • +1 732 777 1443
  • info@sabinsa.com

CERTIFICATES

Certificate Logos Certificate Logos Certificate Logos Certificate Logos

CONTACT US